Dr. Izrael Joined Kadimastem in 2009. Prior to joining Kadimastem, as part of her doctoral work at the Weizmann Institute of Science in the laboratory of Prof. Revel, Dr. Izrael was a central part of the team that invented and developed the technology which became the basis for Kadimastem’s cell therapy product for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. At Kadimastem she served as the head of the drug screening team, based on human oligodendrocytes (Myeling forming cells), and in 2012 was appointed to run the neurodegenerative department at Kadimastem, responsible for Kadimastem’s cell product for ALS. In 2017 she was appointed as VP for Research and Development for ALS and Neurodegenerative Diseases. Dr. Izrael holds a PhD in molecular genetics from the Weizmann Institute of Science and M.Sc. in Neurobiology from the Hebrew University of Jerusalem. Dr. Izrael has published 16 scientific papers and patents in the field of neurobiology and development of technologies based on stem cell derivatives for the treatment of central nervous system disease and drug screening.
Michal Izrael
